Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 18/20 | 0.50 |
| ▸ | PRKAA2 | P54646 | 18/20 | 0.50 |
| ▸ | PRKAB1 | Q9Y478 | 18/20 | 0.50 |
| ▸ | HMGCR | P04035 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15776448 | 0.94 | PRKAG1 (0.55) | PRKAG1PRKAA2PRKAB1HMGCR | |
| SCHEMBL14976244 | 0.91 | HMGCR (0.49) | PRKAG1PRKAA2PRKAB1HMGCR | |
| SCHEMBL21980429 | 0.88 | PRKAG1 (0.44) | PRKAG1PRKAA2PRKAB1 | |
| SCHEMBL20588833 | 0.81 | PRKAG1 (0.49) | PRKAG1PRKAA2PRKAB1 | |
| SCHEMBL17597866 | 0.78 | NR1H3 (0.38) | PRKAG1PRKAA2PRKAB1HMGCR | |
| SCHEMBL20553014 | 0.78 | HMGCR (0.48) | PRKAG1PRKAA2PRKAB1HMGCR | |
| SCHEMBL17597110 | 0.78 | PRKAG1 (0.53) | PRKAG1PRKAA2PRKAB1HMGCR | |
| SCHEMBL16533990 | 0.77 | HMGCR (0.45) | PRKAG1PRKAA2PRKAB1HMGCR | |
| SCHEMBL23795763 | 0.77 | HMGCR (0.47) | PRKAG1PRKAA2PRKAB1HMGCR | |
| SCHEMBL20552574 | 0.76 | HMGCR (0.50) | PRKAG1PRKAA2PRKAB1HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218414-A1 | METHODS FOR MAKING HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED | 2024-07-04 | — | — | US | disclosed |
| US-11060124-B2 | Methods for making high intensity sweeteners | FIRMENICH INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| US-10662458-B2 | Methods and materials for biosynthesis of mogroside compounds | EVOLVA SA (CH) | 2020-05-26 | — | — | US | disclosed |
| US-10465222-B2 | Methods and materials for biosynthesis of mogroside compounds | EVOLVA SA (CH) | 2019-11-05 | — | — | US | disclosed |
| US-9932619-B2 | Methods and materials for biosynthesis of mogroside compounds | EVOLVA SA (CH) | 2018-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11060124-B2 | Methods for making high intensity sweeteners | OXER1, MAN1B1, GMDS | PRKAG1 1166/4885PRKAA2 2993/4885PRKAB1 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.